Keywords
Gastrointestinal, Malignant, immunohistochemistry, Imatinib, Mutation
Abstract
Gastrointestinal stromal tumors (GISTs) are rare, making up less than 1% of all gastrointestinal tumors. Each year, approximately 4,000 to 6,000 adults in the United States will be diagnosed with a GIST. However, they are common mesenchymal tumors accounting for 80% of gastrointestinal mesenchymal tumors, as well as comprising 3-5% of all sarcomas and 1% of all gastrointestinal neoplasms. GISTs can occur along any location in the GI tract, but most GISTs are found in the stomach (60%), as well as the jejunum and ileum of the small intestine (20-30%). This case describes a 49-year-old male who presents with a malignant recurrent GIST two years after resection of a primary GIST. GISTs represent a problematic subset of gastrointestinal neoplasms due to the variability of immunohistochemistry and cytogenetics of the tumors across patients. GISTs should always be included in the differential diagnosis of presentation of a gastrointestinal mass. Early detection combined with complete resection of the mass, administration of tyrosine kinase inhibitors, as well as observation for possible recurrence is considered the current standard of care in patients with GIST.
Citation
Green C, Palagonia N, Stastka P, Cevallos A, O’Grady E, et al. (2021) Malignant Gastrointestinal Stromal Tumor: Case Report with Uncommon Presentation and Review of the Literature. SM J Sarcoma Res 5: 5.